Amersham Plc

Richard Pither

Alexander Mark Gibson

Marivi Mendizabal

Susan Champion

Philip Duncanson

Shirley Elizabeth Pullan

Vaughan Griffiths

Compounds of formula (I) where: X is OH or SH or NH or &mdash;L-Z; X and X are the same or different and each is H, C alkyl, benzyl a protecting group or &mdash;L-Z, X is H or C alkyl, L is a linker comprising a chain of 0-10 atoms, Z is a group comprising a detectable moiety which comprise at least one detectable moiety are useful in the diagnosis and prognosis and radiotherapy of metastatic bone disease.

Labelled ascorbic acid derivatives

The present invention relates to P or P-labelled bisphosphonates as radiotherapeutic radiopharmaceuticals. The P- or P-labelled bisphosphonates, which are chemically identical to the unlabelled agent, are expected to target the lesion site in an identical manner, but also deliver a significant radiocytotoxic effect to the surrounding cells. This should result, given the favorable energetics of the &bgr; particle emission from the P nuclide, in a loss of proliferative capacity of cells associated with the tumor lesion. The relative stability and in vivo localisation of bisphosphonates makes them good candidates as P/ P delivery vehicles.

Radiolabelled bisphosphonates and method

Growing community of inventors

Amersham, United Kingdom

Richard Pither